A LinkedIn post from Tubulis indicates that clinical data for its antibody-drug conjugate TUB-040 will be featured in a poster presentation at the 27th Annual ESGO Congress in Copenhagen from February 26-28, 2026. The poster will reportedly cover the dose-escalation portion of an ongoing Phase 1 study in patients with platinum-resistant high-grade serous ovarian carcinoma.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post notes that the principal investigator, Dr. Antonio González Martín of the University of Navarra, will present the data, and describes TUB-040 as a NaPi2b-targeting ADC built on Tubulis’ proprietary Tubutecan technology. For investors, visibility at a major gynecological oncology meeting may signal advancing clinical execution and could help position TUB-040 within a competitive ovarian cancer ADC landscape.
While the post does not disclose efficacy or safety outcomes, the focus on dose-escalation Phase 1 results suggests the program is progressing through early clinical milestones. Positive reception or follow-on data from this trial could influence future partnering opportunities, non-dilutive funding prospects, and Tubulis’ ability to attract later-stage development capital in the ADC segment.